Strontium and strontium ranelate: Historical review of some of their functions

Pilmane, Māra; Šalma-Ancāne, Kristīne; Loča, Dagnija; Ločs, Jānis; Bērziņa-Cimdiņa, Līga

doi:10.1016/j.msec.2017.05.042

Cited by 189 publications

(150 citation statements)

References 100 publications

Supporting

Mentioning

126

Contrasting

Unclassified

Order By: Relevance

“…In particular, Sr increases the expression of OPG and decreases the one of RANKL in osteoblasts, which results as indirect role on osteoclast formation and activity. [40] The results of our in vitro coculture model demonstrated that strontium is able to display its anti-osteoporotic activity also when embedded as SrHA in gelatin-based scaffolds, affecting osteoclasts via both a direct action and indirect effects mediated by osteoblasts. When compared to G_HA and G_ HA_G, scaffolds containing SrHA showed an enhancement of osteoblast activity and a reduction of both number and differentiation of osteoclast from monocytes precursors, mainly due to promotion of OPG expression.…”

Section: Osteoblast and Osteoclast Activitymentioning

confidence: 77%

“…Sr promotes bone formation inducing higher osteoblast proliferation and stimulating osteoblast activity, through different pathways, such as the activation of the Ca‐sensing receptor, of MAPK and ERK signaling, and the modulation of the expression of Runx‐2 gene and of the OPG/RANKL system. In particular, Sr increases the expression of OPG and decreases the one of RANKL in osteoblasts, which results as indirect role on osteoclast formation and activity …”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Strontium‐Substituted Hydroxyapatite‐Gelatin Biomimetic Scaffolds Modulate Bone Cell Response

Panzavolta

Torricelli

Casolari

et al. 2018

Macromolecular Bioscience

View full text Add to dashboard Cite

Strontium has a beneficial role on bone remodeling and is proposed for the treatment of pathologies associated to excessive bone resorption, such as osteoporosis. Herein, the possibility to utilize a biomimetic scaffold as strontium delivery system is explored. Porous 3D gelatin scaffolds containing about 30% of strontium substituted hydroxyapatite (SrHA) or pure hydroxyapatite (HA) are prepared by freeze-drying. The scaffolds display a very high open porosity, with an interconnectivity of 100%. Reinforcement with further amount of gelatin provokes a modest decrease of the average pore size, without reducing interconnectivity. Moreover, reinforced scaffolds display reduced water uptake ability and increased values of mechanical parameters when compared to as-prepared scaffolds. Strontium displays a sustained release in phosphate buffered saline: the quantities released after 14 d from as-prepared and reinforced scaffolds are just 14 and 18% of the initial content, respectively. Coculture of osteoblasts and osteoclasts shows that SrHA-containing scaffolds promote osteoblast viability and activity when compared to HA-containing scaffolds. On the other hand, osteoclastogenesis and osteoclast differentiation are significantly inhibited on SrHA-containing scaffolds, suggesting that these systems could be usefully applied for local delivery of strontium in loci characterized by excessive bone resorption.

show abstract

Section: Osteoblast and Osteoclast Activitymentioning

confidence: 77%

Section: Resultsmentioning

confidence: 99%

Strontium‐Substituted Hydroxyapatite‐Gelatin Biomimetic Scaffolds Modulate Bone Cell Response

Panzavolta

Torricelli

Casolari

et al. 2018

Macromolecular Bioscience

View full text Add to dashboard Cite

show abstract

“…Hence, there is an unceasing search for medications that can effectively treat osteopenia/osteoporosis, reducing the fracture risk at all skeletal sites, with minimal contraindications, maximum tolerability, and the best risk‐benefit balance . During the last decade, several reports have investigated strontium ranelate as an antiosteoporosis drug due to its promising physicochemical and pharmacokinetic features . When compared to other drugs, strontium ranelate has a very peculiar dual action on bone tissues that simultaneously stimulates osteoblast recruitment and activity while the number, activity, and lifespan of osteoclasts are reduced, resulting in both anabolic and anti‐resorptive actions …”

Section: Introductionmentioning

confidence: 99%

“…11 During the last decade, several reports have investigated strontium ranelate as an antiosteoporosis drug due to its promising physicochemical and pharmacokinetic features. 12 When compared to other drugs, strontium ranelate has a very peculiar dual action on bone tissues that simultaneously stimulates osteoblast recruitment and activity while the number, activity, and lifespan of osteoclasts are reduced, resulting in both anabolic and anti-resorptive actions. 13,14 In the field of dentistry, previous studies in animals demonstrated that the administration of strontium ranelate decreased parameters of bone resorption in the alveolar bone, 15 improved peri-implant bone quality and osseointegration, 16,17 reduced the tooth movement and root resorption during orthodontic movement, 18 and accelerated new bone formation in the expanded mid-palatal suture.…”

Section: Introductionmentioning

confidence: 99%

Effects of strontium ranelate on ligature‐induced periodontitis in estrogen‐deficient and estrogen‐sufficient rats

Marins

Napimoga

Malta

et al. 2019

J of Periodontal Research

View full text Add to dashboard Cite

Background and objectives Strontium ranelate is a medication indicated for the treatment of osteoporosis that presents concomitant anti‐resorptive and osteoanabolic dual biological activity. However, the effects of strontium ranelate on alveolar bone have been poorly explored. Furthermore, to date, there are no data on the effects of this medication on alveolar bone loss (BL) during conditions of estrogen deficiency. Therefore, the aim of this study was to evaluate the effects of strontium ranelate on ligature‐induced periodontitis in estrogen‐deficient and estrogen‐sufficient rats. Methods Ninety‐six rats were assigned to one of the following groups: sham‐surgery + water (estrogen‐sufficient; n = 24); ovariectomy + water (estrogen‐deficient; n = 24), sham‐surgery + strontium ranelate (ranelate/estrogen‐sufficient; n = 24) and; ovariectomy + strontium ranelate (ranelate/estrogen‐deficient; n = 24). The rats received strontium ranelate or water from the 14th day after ovariectomy until the end of the experiment. On the 21st day after ovariectomy, one first mandibular molar received a ligature, while the contralateral tooth was left unligated. Eight rats per group were killed at 10, 20, and 30 days after ligature placement. Bone loss (BL) and trabecular bone area (TBA) were analyzed in the furcation area of ligated and unligated teeth at all experimental times by histometry. Tartrate‐resistant acid phosphatase (TRAP) positive cells and immunohistochemical staining for osteocalcin (OCN), osteopontin (OPN), osteoprotegerin (OPG), and receptor activator of NF‐КB ligand (RANKL) were assessed in the ligated teeth at 30 days after ligature placement. Results At 10 and 30 days, ligated teeth of the estrogen‐deficient group exhibited higher BL, when compared to all other groups (P < .05). At 10 days, TBAs were higher in the unligated teeth of strontium ranelate‐treated groups, when compared to those of untreated groups (P < .05). At 30 days, the ligated teeth of the estrogen‐deficient group exhibited lower TBA than the other groups (P < .05). There were no differences among groups regarding the number of TRAP‐stained cells (P < .05). The strontium ranelate‐treated groups exhibited lower expressions of OCN and RANKL than the untreated groups (P < .05). The estrogen‐sufficient group presented higher staining for OPG than both treated and untreated estrogen‐deficient groups (P < .05). Conclusions Strontium ranelate prevented ligature‐induced BL in an estrogen‐deficiency condition and, to a certain extent, increased TBA in the presence and absence of periodontal collapse in states of estrogen deficiency and estrogen sufficiency. Furthermore, strontium ranelate also affected the expression of bone markers, appearing to have acted predominantly as an anti‐resorptive agent.

show abstract

“…Extensive studies are described in the literature demonstrating the ability of this material to allocate metallic ions in its unit cell in order to provide new characteristics to the material. [7][8][9] The theoretical study developed by Reginster et al 10 safety and effectiveness of the treatment of this pathology through the use of Sr ranelate. [7][8][9] The theoretical study developed by Reginster et al 10 safety and effectiveness of the treatment of this pathology through the use of Sr ranelate.…”

Section: Introductionmentioning

confidence: 99%

⁸⁹Sr‐doped hydroxyapatite nanoparticles as a potential therapeutic agent for bone tumors

Rezende

Andrade

Cipreste

et al. 2019

Int J Applied Ceramic Tech

View full text Add to dashboard Cite

Hydroxyapatite (HA) nanoparticles have been studied due to their high biocompatibility, similarity with bone tissue, and their capacity for bone regeneration since these nanoparticles can easily adhere on osteosarcoma and osteoblast cells, promoting osteoblast growth and osteosarcoma cell uptake. These materials may still accumulate spontaneously and selectively in regions of bone tumors through the enhanced permeability and retention effect. HA also allows the incorporation of strontium in your network. Strontium as a biochemical analog of calcium can maintain the osteogenesis characteristics of HA allowing the production of the radioactive isotopes strontium‐89 and phosphorus‐32 through neutron irradiation. These radioisotopes are beta emitters that enable the treatment of bone tumors, while the affected region is regenerated. In this work, we investigated the synthesis of strontium‐doped HA nanorods through the hydrothermal coprecipitation method as a potential therapeutic agent for bone tumors. All materials were successfully obtained and demonstrated high cell viability, maintaining the osteogenic capacity, making these materials promising agents for the specific treatment of bone tumors. The results indicate that the Sr provides an increase in therapeutic potential due to its beta emission.

show abstract

Strontium and strontium ranelate: Historical review of some of their functions

Cited by 189 publications

References 100 publications

Strontium‐Substituted Hydroxyapatite‐Gelatin Biomimetic Scaffolds Modulate Bone Cell Response

Strontium‐Substituted Hydroxyapatite‐Gelatin Biomimetic Scaffolds Modulate Bone Cell Response

Effects of strontium ranelate on ligature‐induced periodontitis in estrogen‐deficient and estrogen‐sufficient rats

⁸⁹Sr‐doped hydroxyapatite nanoparticles as a potential therapeutic agent for bone tumors

Contact Info

Product

Resources

About

Strontium and strontium ranelate: Historical review of some of their functions

Cited by 189 publications

References 100 publications

Strontium‐Substituted Hydroxyapatite‐Gelatin Biomimetic Scaffolds Modulate Bone Cell Response

Strontium‐Substituted Hydroxyapatite‐Gelatin Biomimetic Scaffolds Modulate Bone Cell Response

Effects of strontium ranelate on ligature‐induced periodontitis in estrogen‐deficient and estrogen‐sufficient rats

89Sr‐doped hydroxyapatite nanoparticles as a potential therapeutic agent for bone tumors

Contact Info

Product

Resources

About

⁸⁹Sr‐doped hydroxyapatite nanoparticles as a potential therapeutic agent for bone tumors